Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2007-11-20
2007-11-20
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S021000
Reexamination Certificate
active
10809777
ABSTRACT:
The present invention provides methods of detecting an amyloid peptide-related neurological disorder in an individual; and methods for staging an amyloid peptide-related neurological disorder in an individual. The methods involve detecting a level of a calcium-responsive gene product, such as calbindin, in a hippocampal neuron, especially a granule cell of the dentate gyrus. The invention further provides identifying an agent that treats an amyloid peptide-related neurological disorder, as well as agents identified by the methods.
REFERENCES:
patent: WO 96/40896 (1996-12-01), None
Ristevski S, Making better transgenic models, 2005, Molecular Biotechnology, vol. 29, pp. 153-163.
Smith KR, Gene transfer in higher animals: theoretical considerations and key concepts, J. of Biotechnology, vol. 99, pp. 1-22.
Houdebine LM, The methods to generate transgenic animals and to control transgene expression, 2002, J. of Biotechnology, vol. 98, pp. 145-160.
Montoliu L, Gene transfer strategies in animal transgenesis, 2002, Cloning and Stem Cells, vol. 4, pp. 39-46.
Palop JJ, Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly lined to Alzheimer's disease-related cognitive deficits, 2003, PNAS, vol. 100, pp. 9572-9577.
Mucke L, High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, 2000, J. of Neuroscience, vol. 20, pp. 4050-4058.
Vezzani A, Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y, 2002, Neuroscience, vol. 110, pp. 237-243.
Lamb L, Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice, 1997, Human Molecular Genetics, vol. 6, pp. 1535-1541.
Palop et al. (2003)Proc. Natl. Acad. Sci. USA100:9572-9577.
Barski et al. (2003)J. Neuroscience23:3469-3477.
Moechars et al. (1999)J. Biol. Chem. 274(10):6483-6492.
Mikkonen et al. (1999)Neuroscience92(2):515-32.
Ichimiya, et al. (1998)Brain Res. 475, 156-159.
Hof, P. R. & Morrison, J. H. (1991)Exp. Neurol. 111, 293-301.
Baimbridge KG, et al. (1992) Trends Neurosci 15: 303-308.
Crabbe et al. (1999)Science284:1670-1672.
Wahlsten et al. (2003)J. Neurobiol. 54:283-311.
Vig PJS, et al. (2001) Brain Res. Bull. 56:221-225.
Thoms V, et al, Neuropathology. Sep. 2001;21(3):203-11.
Potier B, et al. (1994) Brain Res 661:181-188.
Pasti L, et al. (1999) Neuroreport 10:2367-2372.
Nägerl UV, et al. (2000) J Neurosci 20:1831-1836.
Nägerl UV, and Mody I (1998) J Physiol 509:39-45.
Mucke L, et al. (2000) J Neurosci 20:4050-4058.
Molinari S, et al. (1996) Proc Natl Acad Sci USA 93:8028-8033.
Magloczky Z, et al. (1997) Neuroscience 76:377-385.
Lledo P-M, et al. (1992) Neuron 9:943-954.
Klapstein GJ, et al. (1998) Neuroscience 85:361-373.
Iritani S, et al, Neuropathology. Sep. 2001;21(3):162-7.
Iacopino AM, and Christakos S (1990) Proc Natl Acad Sci USA 87:4078-4082.
Hsia A, et al. (1999) Proc Natl Acad Sci USA 96:3228-3233.
Heyser CJ, et al. (1997) Proc Natl Acad Sci USA 94:1500-1505.
Heizmann CW, and Hunziker W (1991) Trends Biochem Sci 16:98-103.
Guo Q, et al. (1998) Proc Natl Acad Sci USA 95:3227-3232.
Greene JRT, et al. (2001) Neuropathol Appl Neurobiol 27:339-342.
Geula C, et al. (2003) JCompNeurol 455:249-259.
German DC, et al. (1997) Neuroscience 81:735-743.
Chard PS, et al. (1995) Proc Natl Acad Sci USA 92:5144-5148.
Palop et al. “Immunochemical indicators of neuronal and behavioral deficits in transgenic models of Alzheimer's Disease,” Abstract 919 (Jul. 20-25, 2002) The 8thInternational Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden.
West, M. J., Coleman, P. D., Flood, D. G. & Troncoso, J. C. (1994)Lancet344, 769-772.
Dineley K T et al “Beta-amyloid activates the mitogen-activqated protein kinase cascade via hippocampal a7 nicotinic acetylcholine receptors: In vitro and In vivo mechanisms related to Alzheimer's disease” Journal of Neuroscience, New York, NY, vol. 21, No. 12, Jun. 15, 2001, pp. 4125-4133.
Echeverria Valentina et al. “Intracellular A-beta amloid, a sign for worse things to come?” Jul. 31, 1998, Molecular Neurobiology, vol. 26, Nr. 2-3, pp. 299-316.
Berrige, Michael J. “Neuronal calcium signaling” Jul. 1998, Neuron, vol. 21, NR 1, pp. 13-26.
Allen, et al. Elevation of Neuropeptide Y (NPY) in Substania Innominata in Alzheimer's Type Dementia. J. Neurolog. Sciences, 1984, 64, pp. 325-331.
Chan-Palay et al. II “Cortical neurons immunoreactive with antisera against Neuropeptide Y are altered in Alzheimer's-Type Dementia” J. comparative Neurology, 1985, 238, pp. 390-300.
Minthon et al. Cerebrospinal fluid Neuropeptide Y-like Immunoreactive levels in Demential of Alzheimer Type and Dementia with Frontotemporal Degeneration of Non-Alzheimer Type. Demntia, 1990 1 pp. 262-266.
Mucke Lennart
Palop Jorge J.
Borden Paula A.
Bozicevic Field & Francis LLP
Crouch Deborah
Francis Carol L.
Montanari David
LandOfFree
Methods of detecting neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of detecting neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of detecting neurological disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852475